top of page

OpGen's Subsidiary, Curetis, Achieves All Key Milestones in R&D Collaboration with FIND

OpGen, Inc., a renowned name in precision medicine, is making significant strides in the battle against infectious diseases with its German subsidiary, Curetis GmbH. Recently, Curetis reported fulfilling all the key milestones under the initial research and development (R&D) collaboration agreement with FIND.

A Successful Collaboration

The collaboration, which focuses on molecular diagnostics and bioinformatics, has led to the successful development and preliminary wet-lab testing of a Unyvero A30 panel with 33 targets, which includes fully integrated sample preparation.

"We are excited to have successfully delivered the final milestones from the first phase of our collaboration agreement and look forward to working on the next set of deliverables under the expanded scope of our R&D partnership with FIND." - Andreas Boos, Chief Technology Officer at Curetis GmbH

Expansion of the Collaboration

The collaboration is now set to expand with the inclusion of isolates from other sub-Saharan African countries. This expansion will complement the originally planned Next Generation Sequencing (NGS) strain analysis.

Achievements and Milestones

The successful completion of the deliverables triggered a milestone payment of approximately $0.3 million.

  1. Development of Unyvero A30 panel

  2. Successful wet-lab testing

  3. Expansion to include isolates from other sub-Saharan African countries

  4. Milestone payment of $0.3 million

Optimizing for Use in LMICs

The Unyvero A30 instrument underwent multiple adaptations to ensure optimal use in low-and middle-income countries (LMICs). Prototypes of the instrument have been designed, built, and tested for operation in high dust, extended temperature range and power-out scenarios.

Looking Forward

The successful first phase of the collaboration has set a solid foundation for the development of a robust solution optimized for use in LMICs.

"We believe the successful first phase of our development collaboration puts us in an ideal position towards development of a robust solution optimized for use in LMICs, a goal we would like to pursue during a potential next phase of this collaboration under a new agreement with FIND.” - Johannes Bacher, Chief Operating Officer of OpGen

Quality Assurance

The adapted prototype test of the Unyvero A30 has met the quality and accuracy requirements for use in low- and middle-income countries. This was confirmed after evaluating the final milestone data from Curetis.

Future Collaboration

The collaboration might continue to expand testing for bloodstream infections in LMIC hospitals. This would allow patients to be linked to the care they need as soon as possible.

About OpGen

OpGen, Inc. is a precision medicine company working towards combating infectious diseases. With its subsidiaries, Curetis GmbH and Ares Genetics GmbH, it is developing and commercializing molecular microbiology solutions to provide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

OpGen's Product Portfolio

OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform. These products are instrumental in predicting antibiotic response and provide PCR-based SARS-CoV-2 test kits.

print("OpGen's Product Portfolio")
products = ["Unyvero", "Acuitas AMR Gene Panel", "ARES Technology Platform"]
for product in products:


The successful collaboration between OpGen's subsidiary, Curetis, and FIND is paving the way for significant advancements in infectious disease management. The achievements of this collaboration underscore the potential of precision medicine and molecular diagnostics in improving patient outcomes in low- and middle-income countries.

This article is based on publicly available information and is intended for informational purposes only. If any infringement has been made, please contact us for modifications.

For further strategic R&D decision making, consider using Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences


Recent Posts

See All

Biogen's Acquisition of Reata Pharmaceuticals

Introduction In a significant development for the medical community, Biogen Inc. (Nasdaq: BIIB) has announced its definitive agreement to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA). This strat


bottom of page